文献速递生殖医学

体外受精中经验性使用生长激素无效:最大规模随机对照试验

Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial.
PubMed 文献 · Hum Reprod · 2025-01-01

这项在加拿大蒙特利尔Ovo诊所开展的III期开放标签随机对照试验纳入288例预期正常反应的IVF患者,1:1随机分为生长激素组(每日皮下注射2.5 mg至取卵日)和对照组。结果显示两组在促排卵参数、胚胎质量及新鲜和冷冻胚胎移植的着床率、流产率、临床妊娠率和活产率上均无显著差异。

要点

  • 在GnRH拮抗剂方案的预期正常反应人群中,经验性辅助生长激素未改善IVF刺激结果或生殖结局。
  • 新鲜胚胎移植临床妊娠率生长激素组43.6% vs 对照组50.0%(P=0.406),活产率32.1% vs 33.3%(P=0.860)。
  • 首次冷冻胚胎移植临床妊娠率35.1% vs 44.2%(P=0.356),活产率22.8% vs 32.6%(P=0.277)。

核心结论

  • 在GnRH拮抗剂周期的普通IVF人群中,经验性辅助生长激素治疗不改善IVF刺激结果或生殖结局,包括着床率、流产率和临床妊娠率。

研究设计与样本

  • III期开放标签随机对照试验,2014年6月至2020年1月在加拿大蒙特利尔Ovo诊所纳入288例接受拮抗剂IVF周期的预期正常反应患者,1:1随机分组。
  • 干预组从卵巢刺激第1天至取卵日每日皮下注射2.5 mg生长激素,对照组接受标准卵巢刺激不加辅助治疗。

主要发现

  • 促性腺激素总剂量生长激素组4600 IU vs 对照组4660 IU(P=0.752),刺激天数11.4 vs 11.7天(P=0.118),子宫内膜厚度10.63 vs 10.94 mm(P=0.372)。
  • 意向治疗分析中,≥15 mm卵泡数7.8 vs 7.1(P=0.212),获卵数11.7 vs 11.2(P=0.613),成熟卵母细胞数8.5 vs 8.6(P=0.851),成熟率73.8% vs 78.4%(P=0.060),受精率64.3% vs 67.2%(P=0.388),优质胚胎数2.5 vs 2.6(P=0.767)。
  • 新鲜胚胎移植着床率38.2% vs 39.5%(P=0.829),流产率26.5% vs 31.1%(P=0.653),临床妊娠率43.6% vs 50.0%(P=0.406,率差95%CI:-0.06 [-0.22, 0.09]),活产率32.1% vs 33.3%(P=0.860)。
  • 首次冷冻胚胎移植着床率31.6% vs 45.3%(P=0.178),流产率28.6% vs 26.3%(P=0.873),临床妊娠率35.1% vs 44.2%(P=0.356,率差95%CI:-0.09 [-0.28, 0.10]),活产率22.8% vs 32.6%(P=0.277)。

临床怎么用

  • 作者认为,这些发现提示在GnRH拮抗剂周期的卵巢刺激中加入生长激素治疗可能不会使普通IVF人群获益。
  • 作者建议需要更多高质量随机对照试验来识别可能从该治疗中获益的患者亚组。

局限性

  • 研究聚焦于预期正常反应者,限制了其对其他患者群体(如低反应者)的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does adjuvant growth hormone (GH) therapy in GnRH antagonist cycles improve reproductive outcomes in the general IVF population? SUMMARY ANSWER: Empiric adjuvant GH therapy in GnRH antagonist cycles does not improve IVF stimulation results or reproductive outcomes, including implantation, miscarriage, and clinical pregnancy rates. WHAT IS KNOWN ALREADY: Previous evidence regarding the benefits of GH therapy in IVF cycles has been inconclusive due to the lack of well-designed, large-scale randomized controlled trials (RCTs) in the general IVF population. STUDY DESIGN, SIZE, DURATION: This is a phase III open-label RCT involving 288 patients undergoing antagonist IVF cycles at the Ovo clinic in Montreal, Canada, between June 2014 and January 2020. Patients were randomly assigned at a 1:1 ratio to either the GH or control group. The intervention group received daily 2.5 mg subcutaneous injections of GH from Day 1 of ovarian stimulation until the day of oocyte retrieval, while the control group received standard ovarian stimulation without any adjuvant therapy. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were expected normal responders. All embryo transfers, both fresh and frozen, resulting from the studied IVF cycle were included in an intention-to-treat and per-protocol analyses. The primary outcome was the clinical pregnancy rate, while secondary outcomes included the number of retrieved oocytes, good-quality embryos, maturation, fertilization, implantation, and miscarriage rates. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 288 patients were recruited and randomly assigned at a 1:1 ratio to either the GH or the control group. After excluding cycle cancellations and patients who did not undergo transfer, 105 patients remained in each group. The overall mean age was 38.0 years, the mean BMI was 25.11 kg/m2 and the mean anti-Müllerian hormone was 2.51 ng/ml. The cycle characteristics were similar between both groups. No differences were observed regarding the total dose of gonadotropins (4600 versus 4660 IU for the GH and control groups, respectively, P = 0.752), days of stimulation (11.4 versus 11.7 days, P = 0.118), and endometrial thickness (10.63 versus 10.94 mm, P = 0.372). Both the intention to treat (ITT) and per protocol analyses yielded similar results for stimulation outcomes. In the ITT analysis, no differences were found in the number of follicles ≥15 mm (7.8 versus 7.1, P = 0.212), retrieved oocytes (11.7 versus 11.2, P = 0.613), mature oocytes (8.5 versus 8.6, P = 0.851), maturation rate (73.8 versus 78.4%, P = 0.060), fertilization rate (64.3 versus 67.2%, P = 0.388), and good quality embryos (2.5 versus 2.6, P = 0.767). Reproductive outcomes in fresh embryo transfer showed no difference for implantation rate (38.2 versus 39.5%, P = 0.829), miscarriage rate (26.5 versus 31.1%, P = 0.653), clinical pregnancy rate (43.6 versus 50.0%, P = 0.406, rate difference, 95% CI: -0.06 [-0.22, 0.09]), and live birth rate (32.1 versus 33.3%, P = 0.860). The number of embryos needed to achieve a clinical pregnancy was 3.0 versus 2.5 in the GH and control groups, respectively. Similarly, reproductive outcomes in first frozen embryo transfer showed no difference for implantation rate (31.6 versus 45.3%, P = 0.178), miscarriage rate (28.6 versus 26.3%, P = 0.873), clinical pregnancy rate (35.1 versus 44.2%, P = 0.406, P = 0.356, rate difference, 95% CI: -0.09 [-0.28, 0.10]), and live birth rate (22.8 versus 32.6%, P = 0.277). The number of embryos needed to achieve a clinical pregnancy was 3.1 versus 2.4 in the GH and control groups, respectively. LIMITATIONS, REASONS FOR CAUTION: The study focused on expected normal responders, limiting its applicability to other patient populations such as poor responders. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that adding GH therapy to ovarian stimulation in GnRH antagonist cycles may not benefit the general IVF population. Additional high-quality RCTs are warranted to identify subgroups of patients who might benefit from this treatment. STUDY FUNDING/COMPETING INTEREST(S): EMD Serono Inc., Mississauga, Canada, supplied Saizen® for the study, free of charge. In addition, they provided funding for the statistical analysis. I-J.K. declares grants or contracts from Ferring Pharmaceuticals, consulting fees from Ferring Pharmaceuticals, honoraria from Ferring Pharmaceuticals and EMD Serono, support for attending meetings or travel from Ferring Pharmaceuticals and EMD Serono, participation on a Data Safety Monitoring Board or Advisory Board for Ferring Pharmaceuticals, and stock or stock options from The Fertility Partners; W.J. declares support for attending meetings or travel from EMD Serono; and S.P. declares stock or stock options from The Fertility Partners. All other authors have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER: NCT01715324. TRIAL REGISTRATION DATE: 25 October 2012. DATE OF FIRST PATIENT’S ENROLMENT: 25 June 2014.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Mourad A, Jamal W, Hemmings R, et al. Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial. Hum Reprod. 2025. PMID: 39673334. doi:10.1093/humrep/deae251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。